Serum uric acid, disease severity and outcomes in COVID-19
Inès Dufour(Cliniques Universitaires Saint-Luc), Halil Yıldız(Cliniques Universitaires Saint-Luc), Julien De Greef(Assistance Publique – Hôpitaux de Paris), Alexis Wérion(Cliniques Universitaires Saint-Luc), Olivier Van Caeneghem, Ludovic Gérard(Cliniques Universitaires Saint-Luc), Fatima Larbaoui, Anastazja Wisniewska(Cliniques Universitaires Saint-Luc), Johann Morelle(University of Namur), Michel Jadoul(Cliniques Universitaires Saint-Luc), Andréa Penaloza(Cliniques Universitaires Saint-Luc), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Marie Perrot(Cliniques Universitaires Saint-Luc), Leïla Belkhir, Christophe Beauloye(Cliniques Universitaires Saint-Luc), Luc‐Marie Jacquet, Christine Collienne, Philippe Hantson(Cliniques Universitaires Saint-Luc), Hector Rodriguez‐Villalobos(Cliniques Universitaires Saint-Luc), Mélanie Dechamps, Jean Cyr Yombi(Cliniques Universitaires Saint-Luc), G. Schmit(Cliniques Universitaires Saint-Luc), Xavier Wittebole(Cliniques Universitaires Saint-Luc), Virginie Montiel, Florence Dupriez, Maximilien Thoma, Lucie Pothen(Cliniques Universitaires Saint-Luc), Benoît Kabamba, Anaïs Scohy(Cliniques Universitaires Saint-Luc)
Cited by 41
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure
|New England Journal of Medicine|2015|2.4k
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
|Kidney International|2007|1.5k
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890